ARIDIS PHARMACEUTICALS INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ARDS and buy or sell other stocks, ETFs, and their options commission-free!

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company was founded by Eric J. 

CEO
Vu L. Truong
CEOVu L. Truong
Employees
37
Employees37
Headquarters
Los Gatos, California
HeadquartersLos Gatos, California
Founded
2003
Founded2003
Employees
37
Employees37

ARDS Key Statistics

Market cap
73.55K
Market cap73.55K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
12.66K
Average volume12.66K
High today
$0.0017
High today$0.0017
Low today
$0.0002
Low today$0.0002
Open price
$0.0002
Open price$0.0002
Volume
30.00
Volume30.00
52 Week high
$0.05
52 Week high$0.05
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

The current ARIDIS PHARMACEUTICALS INC(ARDS) stock price is $0.00, with a market capitalization of 73.55K.

On 2026-05-19, ARIDIS PHARMACEUTICALS INC(ARDS) stock moved within a range of $0.00 to $0.00. With shares now at $0.00, the stock is trading +725.0% above its intraday low and 0.0% below the session's peak.

Trading activity shows a volume of 30, compared to an average daily volume of 12.66K.

The stock's 52-week range extends from a low of $0.00 to a high of $0.05.

The stock's 52-week range extends from a low of $0.00 to a high of $0.05.

People also own

Based on the portfolios of people who own ARDS. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.